Neurological disorders Archives

News and Trends 21 Feb 2023

Biocytogen launches nanobody therapeutics project for 100 targets

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has launched the “Nano 100 Project,” which aims to develop fully human nanobody drugs for more than 100 targets. The project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale. Compared […]

February 21, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Sysnav and Roche partner on movement tracking technology

Sysnav Healthcare and Roche have partnered to develop industry standard outcome measurements in diseases associated with movement impairments, as well as designing the next generation of wearable technology based on Sysnav’s technology. Patients living with a neuromuscular disorder often suffer from movement impairments that fundamentally impact their daily life. Reliable, objective measurements of a patient’s […]

January 26, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

Funding for university to develop new motor neuron disease therapies

Medical research charity LifeArc, the Motor Neurone Disease Association (MND Association) and the My Name’5 Doddie Foundation have jointly awarded £1 million ($1.2 million) to researchers at University College London (UCL) to progress two pioneering new therapies that could help transform the lives of those living with motor neuron disease (MND). The research grants are […]

January 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Team wins $149M contract for National Institute of Neurological Disorders and Stroke

A team consisting of Battelle, AmplifyBio and Andelyn Biosciences has won a seat on an eight-year, $149 million indefinite delivery, indefinite quantity (IDIQ) contract vehicle for the National Institute of Neurological Disorders and Stroke in the U.S. As one of the prime contractors on the multi-award IDIQ, the team will provide manufacturing and nonclinical support […]

January 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

Silo Pharma looks into the 2023 psychedelics crystal ball

Labiotech had the opportunity to ask James Kuo, vice president of R&D at Silo Pharma Inc., about his predictions for the field of psychedelic research in 2023. Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare […]

January 11, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

STALICLA signs agreement with Novartis on neurodevelopmental disorders

STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs). Mavoglurant has previously been tested in more than 1,800 patients and demonstrated a good safety and […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

Watch: IRLAB CEO Richard Godfrey

IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson’s disease. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to […]

December 20, 2022 - 1 minutemin - By Jim Cornall

News and Trends 16 Dec 2022

Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease

Alchemab Therapeutics has been awarded a grant of £1.7 million ($2 million) from Innovate UK’s Biomedical Catalyst (BMC) 2022 funding competition to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease. Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical studies to progress its panel of antibodies towards first […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Charcot-Marie-Tooth study to get $250K grant

The Muscular Dystrophy Association (MDA) and Charcot-Marie-Tooth Research Foundation (CMTRF) have announced joint funding for a study by Alessandra Bolino at San Raffaele Hospital (Ospedale San Raffaele), Italy, on restoring membrane trafficking in Charcot-Marie-Tooth (CMT) neuropathies with aberrant myelin. This will be a three-year study, with the grant totaling $263,450. “We at the Muscular Dystrophy […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

EMA gives Myrtelle’s Canavan disease gene therapy candidate OD designation

Myrtelle Inc., a clinical stage gene therapy company, has announced that the European Medicines Agency (EMA) has granted orphan drug (OD) designation for rAAV-Olig001-ASPA, the company’s lead gene therapy product candidate for the treatment of Canavan disease (CD). EMA OD designation’s aim is to encourage the development of treatments for life-threatening rare conditions by providing […]

December 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

PrecisionLife to work on R&D with Ono Pharmaceutical

PrecisionLife Limited has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyzes multi-modal datasets including genomic, clinical, and epidemiological data to […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurological disorders

Biocytogen launches nanobody therapeutics project for 100 targets

Sysnav and Roche partner on movement tracking technology

Funding for university to develop new motor neuron disease therapies

Team wins $149M contract for National Institute of Neurological Disorders and Stroke

Silo Pharma looks into the 2023 psychedelics crystal ball

STALICLA signs agreement with Novartis on neurodevelopmental disorders

Watch: IRLAB CEO Richard Godfrey

Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease

Charcot-Marie-Tooth study to get $250K grant

EMA gives Myrtelle’s Canavan disease gene therapy candidate OD designation

PrecisionLife to work on R&D with Ono Pharmaceutical

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!